MA
ATNM icon

MUFG Americas’s Actinium Pharmaceuticals ATNM Stock Holding History

MUFG Americas’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-32
Closed -$2K – 1140
2015
Q1 		$2K Buy
32
+7
+28% +$833 ﹤0.01% 1084
2014
Q4 		$4K Buy
25
+11
+79% +$2.09K ﹤0.01% 1111
2014
Q3 		$3K Buy
+14
New +$2.78K ﹤0.01% 1151

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MUFG Americas's ATNM Position: Q2 2015 in Review

MUFG Americas sold out of Actinium Pharmaceuticals (ATNM) in Q2 2015, closing a stake of 32 shares — an estimated $2K sold.

MUFG Americas first reported a position in ATNM in Q3 2014 and held it in 3 quarters. The position peaked at $4K in Q4 2014. 39 funds tracked by Wall St. Rank hold ATNM as of Q2 2015.

  • MUFG Americas reported no remaining Actinium Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • MUFG Americas sold 32 Actinium Pharmaceuticals shares in Q2 2015, an estimated $2K.
  • MUFG Americas first reported a position in Actinium Pharmaceuticals in Q3 2014 and held it in 3 quarters.
  • MUFG Americas's Actinium Pharmaceuticals position peaked at $4K in Q4 2014.
  • 39 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2015.

Based on MUFG Americas's 13F filing for Q2 2015, filed 13 Aug 2015.